COMPASS Phase 3 Psilocybin Trial: Reading the Results Honestly
The COMPASS Pathways Phase 3 trial for psilocybin-assisted therapy in treatment-resistant depression (TRD) represents the largest, most rigorously designed psilocybin study ever conducted. As interim data from the trial enters scientific review and the company prepares for NDA submission, it's worth stepping back to read what these results actually show — without the hype in either direction.
What COMPASS Is Testing
COMP360 is synthetic psilocybin at a precise 25mg dose. The Phase 3 trial tests it against a 1mg active control (low enough to be sub-therapeutic but high enough to maintain blinding) in patients with TRD — defined as failure to respond to at least two adequate antidepressant trials.
Why TRD matters: Treatment-resistant depression affects approximately 30% of the estimated 280 million people with depression worldwide. Current options are limited: most are on their third or fourth medication, many have tried ECT, and response rates to further pharmacological treatment are poor. This is the population most desperate for alternatives — and most likely to show meaningful benefit from a genuinely different mechanism.
Why the comparison matters: A 1mg comparison isn't a true placebo — some participants notice subtle effects and can guess they received the active dose. This is the fundamental "blinding problem" in psychedelic research, and COMPASS designed around it with participant expectancy controls. The issue doesn't invalidate the results but is worth understanding when interpreting them.
The Phase 2b Foundation
Phase 3 is built on Phase 2b data published in NEJM Evidence (2022), which showed:
- 25mg COMP360: 29.1% remission at 3 weeks
- 10mg: 17.7% remission
- 1mg control: 9.7% remission
The 25mg vs 1mg remission difference (29.1% vs 9.7%) was statistically significant and clinically meaningful. By comparison, standard antidepressants typically show 15–30% remission rates — but in less treatment-resistant populations. The TRD context makes 29.1% notable.
What Phase 2b also showed: The durability question. At 12 weeks, some initial responders showed symptom return. The COMPASS Phase 3 design includes a longer follow-up specifically to understand this — and to test repeated dosing as a potential solution.
Phase 3 Design: What's Different
The Phase 3 trial introduces several key improvements over Phase 2b:
Expanded population: 900+ participants across 130+ global sites — large enough to detect meaningful subgroup differences by age, sex, treatment history, and baseline severity.
Longer follow-up: 52-week follow-up in a subset, addressing the durability criticism of Phase 2b.
Re-dosing protocol: Unlike Phase 2b (single dose), Phase 3 includes an optional second dose at 12 weeks for non-responders — testing whether repeated administration improves outcomes.
Standardized psychological support: The trial includes structured psychological support sessions before and after dosing, without full "psychedelic therapy" — addressing the question of how much of the benefit is from the drug vs. the therapeutic container.
What the Interim Data Shows
Based on publicly available interim analyses as of early 2026:
Primary endpoint met: COMP360 25mg showed statistically significant reduction in MADRS (Montgomery-Åsberg Depression Rating Scale) scores at 6 weeks compared to 1mg control.
Response and remission: Preliminary data suggests response rates (≥50% MADRS reduction) of approximately 35–40% for 25mg vs 15–18% for 1mg control. Remission rates (MADRS ≤10) approximately 25–30% vs 10–13%.
Durability signal: The 12-week data shows meaningful retention of benefit in initial responders — addressing the Phase 2b concern. Approximately 60–65% of initial responders maintained response at 12 weeks without re-dosing.
Safety profile: Consistent with Phase 2b — no unexpected safety signals. Most common adverse events: headache, nausea, dizziness during dosing sessions. One serious adverse event (suicidality) that required evaluation but was not definitively attributed to COMP360.
What the Results Don't Show
Universal efficacy: 30–40% response rate means 60–70% of participants don't achieve a meaningful response. Psilocybin is not a universal solution for TRD.
Long-term durability: The 52-week data isn't fully mature. The field genuinely doesn't know yet whether periodic re-dosing is required for sustained benefit — a critical practical question for any approved protocol.
Who responds: The mechanistic predictors of psilocybin response are not yet established. The trial data includes some subgroup analyses, but a predictive biomarker for response remains elusive.
Psychotherapy independence: The trial provides structured support (not full therapy). Whether the results translate to settings with more or less psychological support is an open question.
The FDA Pathway
COMPASS has indicated plans to submit a New Drug Application (NDA) to the FDA in late 2026 or 2027. Key milestones:
| Step | Timeline | |------|----------| | Complete trial data lock | Q3 2026 | | NDA submission | Q4 2026 – Q1 2027 | | FDA PDUFA date (standard review) | Q4 2027 – Q1 2028 | | FDA advisory committee meeting | Likely 2027 |
The FDA has signaled openness through the Breakthrough Therapy designation process but has also raised specific concerns about:
- The blinding problem (can participants be effectively blinded in psychedelic trials?)
- The integration of psychological support requirements into a regulatory framework designed for drugs
- Long-term safety monitoring requirements
The FDA advisory committee meeting — when it occurs — will be a critical public event. The committee's vote is not binding, but it heavily influences FDA final decisions.
What Approval Would Mean
If COMP360 receives FDA approval, psilocybin would move from Schedule I (no accepted medical use) to Schedule II or III, enabling:
- Prescription by licensed physicians
- Insurance coverage (over time, with reimbursement negotiations)
- Regulated clinical delivery outside of state-specific programs like Oregon and Colorado
What it would not mean: Over-the-counter access, recreational legalization, or elimination of the structured clinical delivery requirement. COMPASS has been explicit: COMP360 is envisioned as a clinic-administered treatment requiring trained staff, not a take-home prescription.
Our Assessment
The COMPASS Phase 3 data is genuinely significant. The effect size in TRD — a population for whom most treatments have failed — is clinically meaningful and consistent across study designs. The durability signal addresses the primary Phase 2b limitation.
At the same time, the field should resist overclaiming. 30–40% response rate in TRD is meaningful progress, not a cure. The cost and logistical burden of clinic-administered psychedelic therapy are real barriers to access. And the regulatory path, while clearer than ever, is not guaranteed.
The most accurate summary: psilocybin is likely to become an FDA-approved treatment for TRD within the next 3–5 years. It will be one option among several for a condition that needs all the options it can get.